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Abstract
Human DDX3 is a DEAD (Asp-Glu-Ala-Asp)-box RNA helicase that appears to be a prime target for viral
manipulation. While two viruses that manifest major global health threats, HIV and HCV (hepatitis C virus),
utilize DDX3 for their replication, other viruses inhibit DDX3’s newly identified function in innate antiviral
signalling. This review discusses the role of DDX3 in antiviral immunity and its inhibition or exploitation by
different viruses.
Introduction
DDX3(X), or DBX, is a member of the DEAD (Asp-
Glu-Ala-Asp)-box helicase family and was first identified
in 1997 [1]. DEAD-box helicases are involved in a large
variety of cellular processes involving RNA, such as
splicing, mRNA export, transcriptional and translational
regulation, RNA decay and ribosome biogenesis [2]. DDX3
itself has been implicated in nearly all of these processes;
however, the extent of its involvement and its exact
mechanism of action is unclear for most of them [3].
Therefore it is fair to say that we currently lack a solid
understanding of the functions of DDX3 in healthy cells.
However, we and others have recently demonstrated that
DDX3 contributes to antiviral innate immunity [4,5]. This
is particularly interesting because, conversely, DDX3 is
required for the replication of two viruses that pose major
global health threats, namely HIV and HCV (hepatitis C
virus) [6–8]. Owing to these findings, the inhibition of
DDX3 has been suggested as a strategy for the deve-
lopment of novel therapeutics against these two viruses [9].
However, DDX3 also has reported roles in the regulation
of protein translation, cell cycle control and apoptosis [3],
in addition to its aforementioned novel function in antiviral
immune signalling. Therefore it seems absolutely crucial to
understand how exactlyDDX3 contributes to these processes
in order to design informed strategies for its therapeutic
inhibition or manipulation. In the past, studying a viral
protein and its host targets has often provided novel insights,
not only about the virus, but also about the function of its host
target. In our case, studying the immunoregulatory function
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of the VACV (vaccinia virus) protein K7 revealed a novel role
for its host target, DDX3, in antiviral immunity [4].
The role of DDX3 in innate immune
signalling
Viral detection by innate immune cells is mediated by
different sets of PRRs (pattern recognition receptors), mainly
endosomal TLRs (Toll-like receptors) and cytoplasmicRLHs
[RIG (retinoic-acid inducible gene)-like helicases], both of
which recognize different classes of viral nucleic acids.
Recently, several cytoplasmic DNA receptors were also
identified that contribute to the immune response against
DNA viruses. The engagement of these different antiviral
PRRs triggers signalling cascades, which result in the
activation of the transcription factors NF-κB (nuclear factor
κB) and IRF3/7 [IFN (interferon) regulatory factor 3/7].
WhileNF-κB activation is a general feature of PRR signalling
resulting in the expression of pro-inflammatory cytokines,
IRF3/7 activation is a hallmark of the antiviral subsets of
PRRs and leads to the induction of type I IFNs, which
are potent antiviral mediators. The kinases TBK1 {TANK
[TRAF (tumour-necrosis-factor-receptor-associated factor)-
associated nuclear factor-κB activator]-binding kinase 1} and
IKKε [IκB (inhibitor of NF-κB) kinase ε] phosphorylate
and activate IRF3/7 downstream of TLR3, TLR4, the RLHs
and (most likely) the cytoplasmic DNA receptors (Figure 1).
Many viruses have evolvedmechanisms to evade this immune
response, either by avoiding recognition or by actively
interfering with IFN induction or signalling. The VACV
protein K7 potently inhibits IRF3/7 activation and IFNβ
promoter activation induced by a range of different antiviral
PRRs [4]. The identification of DDX3 as a molecular host
target of K7 allowed us to implicate DDX3 in the antiviral
signalling pathway leading to type I IFN induction [4].
We showed that DDX3 transiently associates with IKKε
after virus stimulation. Knockdown of endogenous DDX3
using siRNA (small interfering RNA) led to decreased
induction of the IFNβ promoter and IRF3/7-mediated
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transactivation. This, together with the finding that K7
blocks Sendai virus-induced IRF3 phosphorylation, pointed
towards an involvement of DDX3 in IKKε-induced IRF3/7
activation and, consequently, IFNβ promoter activation [4].
Concurrently, Soulat et al. [5] identified DDX3 as a TBK1
phosphorylation target. Their study also confirmed a role for
DDX3 in PRR-induced IFNβ promoter activation and its
function downstream of TBK1/IKKε [5]. Interestingly, they
showed that DDX3 associates with the IFNβ promoter after
PRR stimulation [5], suggesting that it acts as a transcriptional
cofactor after activation by TBK1/IKKε (Figure 1). There
is other evidence suggesting that DDX3 can indeed act as
a transcriptional co-activator at the promoter level, e.g. it
has been shown to be recruited to the promoter of the
tumour suppressor p21/waf in an Sp1 (specificity protein
1)-dependent manner [10] and to bind and repress the E-
cadherin promoter [11]. Therefore this could be a conceivable
mechanism of action for DDX3. On the other hand, it
has also recently been suggested that DDX3 acts in fact
upstream of IKKε/TBK1 at the level of RIG-I and IPS-1
(IFNβ promoter stimulator-1) [12]. In a yeast two-hybrid
screen, Oshiumi et al. [12] identified DDX3 as a protein
that interacts with the CARD (caspase recruitment domain)
domain of IPS-1, the mitochondrial adaptor molecule that
mediates the initial signalling step after RLH triggering. Like
all DEAD-box helicases and DExD/H-box helicases, DDX3
binds to RNA and potentially also DNA [13]. Oshiumi
et al. [12] postulated that DDX3 acts as a sensor of viral
RNAs and interacts with the RLHs, RIG-I and mda-5
(melanoma differentiation associated gene), and their adaptor
molecule IPS-1 to initiate signalling. While RIG-I levels
in uninfected cells are low and get up-regulated by IFNs
during the course of viral infection, DDX3 is constitutively
expressed in most cells at relatively high levels. Oshiumi
et al. [12] therefore suggest that DDX3 senses viral RNA
and facilitates signalling through IPS-1 at the initial stages of
the infection when RIG-I levels are low (Figure 1).
It is not inconceivable that DDX3 and other DEAD-
box helicases can act as sensors for viral nucleic acids in
the cytosol of infected cells, much in the same way the
related DExD/H helicases RIG-I and mda-5 do. Two more
DExD/H helicases, DHX36 and DHX9, have recently been
shown to sense viral DNA (CpG-A andCpG-B respectively)
in the cytosol and to couple to the TIR (Toll/interleukin-1
receptor)-adaptor molecule MyD88 (myeloid differentiation
factor 88) for signalling [14]. It is therefore quite likely that
additionalDExD/Hhelicases will be discovered to play a role
in RNA/DNA sensing.
However, the role of DDX3 does not appear to be
limited to the sensing of viral RNA and IPS-1-dependent
signalling pathways. DDX3 has also been shown to play a
role in the TRIF (TIR domain-containing adaptor inducing
IFNβ)-dependent TLR4 and TLR3 signalling pathways [4,5]
and ZBP1 (Z-DNA-binding protein 1)-mediated induction
of IFNβ by HCMV (human cytomegalovirus) [15]. In
addition, several of the aforementioned studies support an
involvement of DDX3 downstream of TBK1/IKKε, a point
Figure 1 The role of DDX3 in antiviral innate immune signalling
DDX3 contributes to IRF3/7 activation and IFNβ promoter induction
downstream of different antiviral PRRs. Its exact function and placement
in this signalling pathway remains to be determined, as DDX3
was suggested to act as RNA sensor, signalling intermediate and
transcriptional co-activator. Recently, DDX3 was suggested to detect
viral RNA and interact with IPS-1 to induce signalling in the early stages
of infection [12]. Previously, DDX3 was shown to interact with, and be
phosphorylated by, TBK1 and IKKε, the key kinases that phosphorylate
IRF3/7 in the depicted antiviral signalling pathways [4,5]. The interaction
between DDX3 and IKKε was transiently induced during Sendai virus
(SeV) infection, linking DDX3 into the signalling pathway from RIG-I
to IRF3 activation and IFNβ promoter activation [4]. IKKε and TBK1
also mediate IRF3 activation downstream of other pattern recognition
receptors, such as TLR3 and TLR4 and cytoplasmic DNA receptors such as
ZBP1. Consequently, DDX3 also contributes to IFNβ promoter induction
downstream of these receptors [4,5,15–17]. DDX3 was also found to
associate directly with the IFNβ promoter, suggesting that it can act as
a transcriptional co-activator in this context [5]. The VACV protein K7
binds to the N-terminus of DDX3, which is required for IFNβ promoter
induction. K7 is a potent inhibitor of IRF3 activation and IFNβ
promoter induction. This suggests that K7 binding to DDX3 prevents it
from exerting its effect on IFN induction in a typical viral immune evasion
strategy [4]. The HBV pol was also recently shown to inhibit the function
of DDX3 in this pathway in a manner similar to K7 [16,17]. AP1, activator
protein 1; HCMV, human cytomegalovirus; TRIF, TIR domain-containing
adaptor protein inducing IFNβ. Adapted from [3] with permission.
of convergence for the TLR3/4, RLH and ZBP1 signalling
pathways [4,5,15–17].
So, while the Oshiumi et al. [12] study further supports
a role for DDX3 in antiviral signalling and the induction of
type I IFNs, it also opens up more questions about its exact
function in this pathway: Does it act as a sensor, a signalling
intermediate or a transcriptional regulator? Is it possible
that DDX3 can be involved at three different levels? It is
imaginable that DDX3 senses viral RNA, then orchestrates
the assembly of signalling intermediates at the mitochondria
and finally translocates into the nucleus to exert a direct effect
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on the IFNβ promoter (after being activated byTBK1/IKKε-
mediated phosphorylation). For example, it is an intriguing
possibility that DDX3 could recruit IKKε to IPS-1, possibly
by means of its N- and C-terminal regions respectively
both of which have been suggested by different studies to
be involved in its effect on IFNβ induction [4,12]. Further
investigation of the temporal and spatial orchestration of
these signalling events will clearly be necessary to clarify the
role of DDX3 in this process.
Inhibition of DDX3 by viral proteins
The VACV protein K7
As mentioned above, we have recently identified DDX3 as
a molecular host target for the VACV protein K7, a viral
protein that potently inhibits TLR- and RLH-dependent
IRF3/7 activation and IFNβ promoter induction [4]. This led
us to identify the novel role for DDX3 in this innate immune
signalling pathway as described above [9]. Interestingly, K7
binds to the N-terminal region of DDX3 (amino acids 1–
139) that we found to be required for the effect on the IFNβ
promoter [4]. In a more recent study, we have narrowed
down theK7-DDX3binding site to the regionbetween amino
acids 61 and 90 of DDX3 and shown that two phenylalanine
residues in this region of DDX3 are required for its effect
on IRF activation [18]. K7 therefore seems to target this
region of DDX3 in a typical immune evasion strategy that
the virus has evolved to suppress production of type I IFNs
(Figure 1).
VACV is a ds (double-stranded) DNA virus that replicates
in the cytoplasm, and mda-5 [19] and the newly described
cytoplasmicDNAsensor Ifi16 (IFN-inducible 16) contribute
to IFNβ induction in response to this virus [20]. By targeting
DDX3, K7 is likely to interfere with both of these signalling
pathways, as well as TLR3 and TLR4 signalling, assuming
DDX3 indeed acts downstream of IKKε/TBK1.
The HBV pol
Another viral protein that interacts with DDX3 is the
HBV (hepatitis B virus) pol (polymerase) [21]. HBV is
a hepadnavirus and replication of its genome occurs by
reverse transcription of a pregenomic RNA template. This
occurs entirely within nucleocapsids and is mediated by
HBV pol. The interaction between DDX3 and HBV
pol appeared to be independent of their interaction with
RNA. DDX3 was incorporated into nucleocapsids together
with HBV pol and inhibited the initial step of reverse
transcription in a manner that was dependent on the ATPase
activity of DDX3 [21]. This suggested an antiviral role
of DDX3 in HBV infection; however, it remained unclear
how DDX3 interfered with viral replication. Interestingly, it
has been shown that DDX3 levels are decreased in a fraction
of HBV-induced HCC (hepatocellular carcinoma) cases [22].
It is possible that the virus down-regulates DDX3 levels
to relieve the inhibitory effect of DDX3 on its replication.
As DDX3 is a potential tumour suppressor, this might
contribute to the development of HBV-induced HCC [22].
More recently, it was shown by two independent studies that
HBV pol acts in a similar fashion to VACV K7 and inhibits
IRF3 activation and IFNβ promoter induction by targeting
DDX3. These studies demonstrated that HBV pol disrupts
the interaction between IKKε and DDX3 and support a role
forDDX3downstreamofTBK1/IKKε andupstreamof IRF3
activation (Figure 1) [16,17].
It is currently unclear how and whether this finding is
linked with the effect of DDX3 on HBV genome replication.
It is unlikely that DDX3 exerts its inhibitory effect on HBV
genome replication through IFNs, as ATPase activity of
DDX3was required for this effect but not for IFN induction.
While all three studies support an antiviral role of DDX3
in HBV infection, the two more recent studies indicate
that HBV pol inhibits DDX3 function (in IFN induction),
while the earlier study suggested that DDX3 inhibits HBV
pol function (in the replication of the viral genome). Perhaps,
the DDX3–HBV pol interaction represents a stalemate in the
co-evolution between host and virus, but further studies are
required to ascertain the role of DDX3 in HBV infection.
At present, it is unclear whether disrupting the HBV pol–
DDX3 interaction would benefit the virus (by relieving the
inhibitory effect of DDX3 on genome replication) or the host
(by restoringDDX3 function in the IFN induction pathway).
Exploitation of DDX3 by viruses
HCV and DDX3
HCVcore proteinwas the first viral protein to be described as
aDDX3-interactingprotein [23–25].However, up tonow, the
functional relevance of this interaction is still unclear. HCV
core protein is a structural protein, which forms the viral
nucleocapsid, but there is evidence that the core protein has
other functions, e.g. in the modulation of viral and cellular
gene expression. The three original studies suggested that
HCV core protein targets DDX3 to manipulate splicing
[24], transcriptional [25] or translational regulation [23]
respectively, but their studies were hampered by the scarcity
of data being available on the cellular function of DDX3 at
the time of discovery. HCV core binds to the C-terminus of
DDX3 (amino acids 553–611), and the interaction is mediated
by the N-terminus of HCV core (amino acids 1–40) [24,25].
It has recently been demonstrated that DDX3 is required
for HCV RNA replication [6,7]. This suggested that HCV
utilizes DDX3 for the replication of its RNA (possibly by
unwinding dsRNA species); however, the exact contribution
of DDX3 remained unclear. It is also unclear whether
the DDX3 interaction with HCV core mediates the effect
of DDX3 on HCV replication. It was recently shown that
a JFH1 strain virus (HCV genotype 2a) carrying a mutation
(Y35A) in the core protein that disrupts DDX3 binding has
no replication defect. The mutated virus also continued to
depend on DDX3 for its replication [26]. This would suggest
that the virus can recruit DDX3 for its replication process in
a core protein-independent manner. However, another recent
C©The Authors Journal compilation C©2011 Biochemical Society
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study observed an inhibitory effect of peptides derived from
the DDX3-binding site of HCV core protein in a HCV
replication system based on genotype 1b. The inhibitory
effect of the core-derived peptides was reversed by DDX3
overexpression, suggesting that they were indeed acting by
targeting DDX3 [27]. We will have to await further studies
to clarify the requirement for the DDX3–core interaction in
HCV replication.
HIV rev and DDX3
Interestingly, DDX3 is also an essential host factor for HIV
replication [8]. HIV Rev protein interacts with DDX3 and
the cellular nuclear export protein CRM1 (chromosome
region maintenance 1), and thereby tags unspliced and
partially spliced viral RNAs to this complex for export from
the nucleus. Knockdown of DDX3 inhibited the export
of these HIV RNAs from the nucleus and, consequently,
HIV replication [8]. DDX3’s helicase activity was required
for its role in HIV RNA export, therefore its function
in this process might be to unwind secondary structures
within the HIV RNA or to remove RNA-bound proteins.
It is currently unclear whether DDX3 is also required
for the nuclear export of selected cellular CRM1 cargos,
but it does not appear to have a general function in
protein or RNA export [3]. It is an exciting possibility
that DDX3 could be targeted for the development of
novel anti-HIV therapeutics. Cellular and viral helicases
have been successfully targeted therapeutically in the past
[9], and knockdown of DDX3 in cells can inhibit HIV
replication without affecting cell viability [28]. Two studies
successfully used small-molecule inhibitors directed at the
ATPase activity of DDX3 to inhibit HIV replication [29,30],
which holds some promise for the therapeutic targeting of its
helicase function. However, we will need to understand the
cellular functions of DDX3 much better, in particular
the role of its helicase activity and the physiological role of its
interaction with CRM1, to design therapeutic strategies that
safely target DDX3 in the context of HIV infection.
Concluding remarks
It is fascinating that DDX3 appears to be a prime target
for viral manipulation. So far, four very different viruses
have been shown to interact with DDX3 and to manipulate
its function in very different ways. Two of the viruses
that pose the biggest global health threats, HIV and HCV,
recruit and require DDX3 for their replication. This opens
exciting possibilities for the therapeutic targeting of DDX3.
HIV/HCV co-infections are not uncommon, and it is an
intriguing idea that a drug targeting DDX3 could combat
both viruses simultaneously. On the other hand, DDX3 has
an antiviral role in the induction of type I IFNs. Two viruses,
HBV and poxvirus, have already been shown to target this
function of DDX3 in a typical immune evasion strategy, and
it is not unlikely that additional viruses target DDX3 in this
way. It is also a possibility that viruses recruiting DDX3
for their replication simultaneously sequester it from its
function in antiviral immunity. ForDDX3 to become a viable
therapeutic target in virus infections and/or autoimmunity,
we have to develop a much better understanding of its
multiple functions in order to target them selectively and
with minimal disruption to cell homoeostasis. Studying the
ways viruses target DDX3 may well provide us with useful
insights for developing our own tools to manipulate DDX3
function.
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